Mengmeng (Margaret) Du, ScD

Assistant Attending Epidemiologist

Mengmeng (Margaret) Du, Assistant Attending Epidemiologist

Office Phone



Harvard University

Dr. Du studies inherited and modifiable factors in cancer—particularly colorectal, endometrial, and pancreatic cancers. This work, conducted with international research teams, seeks to understand tumorigenesis and identify individuals who could most benefit from targeted lifestyle modifications or preventive interventions. Dr. Du studies colorectal cancer biology, risk factors, and risk modeling: She co-leads an NIH-funded study in the African Research Group in Oncology (ARGO) of risk factors and tumor mutation profiles for colorectal cancers in Nigeria. She also studies colorectal cancer in European descent individuals using data in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Dr. Du investigates endometrial cancer risk in the Epidemiology of Endometrial Cancer Consortium (E2C2), for which she is PI of the Data Coordinating Center and member of the Executive Committee. She co-leads an NIH-funded study in this population using multiethnic tumor profiling to shed light on the 2-fold higher mortality in Black patients. Dr. Du also studies pancreatic cancer early detection and risk factor identification: She is PI of the MSK Pancreatic Tumor Registry—which since 2002 has continuously performed surveillance and followed at-risk unaffected relatives of pancreatic cancer patients. To support risk factor studies, the Registry additionally includes patients with pancreatic cancer or with intraductal papillary mucinous neoplasms (IPMNs) and cancer-free controls. Finally, Dr. Du studies telomere dynamics in various large, population-based data sources. She co-directs the MSK Quantitative Sciences Summer Undergraduate Research Experience (QSURE), serves on the Scientific Committee for the New York City Epidemiology Forum, and is an Associate Editor for the international journal Cancer Causes & Control.


Representative Publications

  1. Sharma A, Alatise OI, O’Connell K, Ogunleye SG, Aderounmu AA, Samson ML, Wuraola F, Olasehinde O, Kingham TP, Du M. Healthcare utilisation, cancer screening and potential barriers to accessing cancer care in rural South West Nigeria: a cross-sectional study. BMJ Open. 2021;11:e040352.
  2. Jeon J, Du M, Schoen RE, Hoffmeister M, Newcomb PA, Berndt SI, Caan B, Campbell PT, Chan AT, Chang-Claude J, Giles GG, Gong J, Harrison TA, Huyghe JR, Jacobs EJ, Li L, Lin Y, Le Marchand L, Potter JD, Qu F, Bien SA, Zubair N, Macinnis RJ, Buchanan DD, Hopper JL, Cao Y, Nishihara R, Rennert G, Slattery ML, Thomas DC, Woods MO, Prentice RL, Gruber SB, Zheng Y, Brenner H, Hayes RB, White E, Peters U, Hsu L. Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology. 2018;154(8):2152-2164.e19.
  3. Du M, Auer PL (joint lead author), Jiao S, Haessler J, Altshuler D, Boerwinkle E, Carlson CS, Carty CL, Chen YI, Curtis K, Franceschini N, Hsu L, Jackson R, Lange LA, Lettre G, Monda KL; National Heart, Lung, and Blood Institute (NHLBI) Go Exome Sequencing Project; Nickerson DA, Reiner AP, Rich SS, Rosse SA, Rotter JI, Willer CJ, Wilson JG, North K, Kooperberg C, Heard-Costa N, Peters U. Whole-exome imputation of sequence variants identified two novel alleles associated with adult body height in African Americans. Hum Mol Genet. 2014;23(24):6607-15.
  4. Du M, Kraft P, Eliassen AH, Giovannucci E, Hankinson SE, De Vivo I. Physical activity and risk of endometrial cancer in the Nurses’ Health Study. Int J Cancer. 2014;134(11):2707-16.
  5. Nan H, Du M (joint lead author), De Vivo I, Manson JE, Liu S, McTiernan A, Curb JD, Lessin LS, Bonner MR, Guo Q, Qureshi AA, Hunter DJ, Han J. Shorter telomeres associate with a reduced risk of melanoma development. Cancer Res. 2011;71(21):6758-63.

View a full listing of Mengmeng (Margaret) Du’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Mengmeng (Margaret) Du discloses the following relationships and financial interests:

No disclosures meeting criteria for time period

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at

View all disclosures